Drug Trial Radar · NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
572
Planned (sponsor's estimate)
Start
Apr 13, 2022
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Nurix Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Waldenstrom Macroglobulinemia (WM)
- Primary Central Nervous System Lymphoma (PCNSL)
- Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
NX-5948Drug
Oral NX-5948
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with protocol specified dose-limiting toxicitiesTime frame: Up to 24 months
- To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)Time frame: Up to 24 months
- To evaluate the anti-tumor activity of NX-5948 in the dose levels selected for Phase 1b safety expansion based on overall response rate (ORR) as assessed by InvestigatorTime frame: Up to 3 years
- Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deathsTime frame: Up to 6 years
- To further evaluate the anti-tumor activity of NX-5948 in patients with CLL/SLL at the dose identified in Phase 1b Part 1 based on overall response rate (ORR) as assessed by InvestigatorTime frame: Up to 3 years
Locations
62 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
University of Miami
Miami, Florida · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
National Institute of Health
Bethesda, Maryland · Recruiting
Cayuga Medical Center
Ithaca, New York · Withdrawn
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Withdrawn
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
CHU Angers
Angers, France · Recruiting
Hôpital Avicenne
Bobigny, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
CHU Bordeaux
Pessac, France · Recruiting
CHU de Poitiers
Poitiers, France · Recruiting
Institut Curie-Site Saint-Cloud
Saint-Cloud, France · Recruiting
CHRU de Nancy
Vandœuvre-lès-Nancy, France · Recruiting
IRCCS - AOU di Bologna
Bologna, Italy · Withdrawn
ASST Spedali Civili Brescia
Brescia, Italy · Withdrawn
IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano
Milan, Italy · Recruiting
IRCCS Ospedale San Raffaele
Milan, Italy · Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Italy · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Withdrawn
Radboud University Medical Center
Nijmegen, Netherlands · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
University Medical Center Utrecht
Utrecht, Netherlands · Recruiting
Medical University of Lublin
Lublin, Poland · Recruiting
AidPort sp. Zo.o
Skórzewo, Greater Poland Voivodeship, Poland · Recruiting
Pratia MCM
Krakow, Lesser Poland Voivodeship, Poland · Recruiting
University Clinical Hostpital in Wroclaw
Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting
Pratia MTZ
Warsaw, Masovian Voivodeship, Poland · Recruiting
National Institute of Oncology Warszawa
Warsaw, Masovian Voivodeship, Poland · Recruiting
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.